Paraguayan Society of Rheumatology guidelines on use of biologic therapies in rheumatoid arthritis
PDF (Spanish)
HTML (Spanish)

Keywords

Biologic treatment
rheumatoid Arthritis
immunotherapy
autoimmune diseases
drugs
guidelines

How to Cite

1.
de Abreu P. Paraguayan Society of Rheumatology guidelines on use of biologic therapies in rheumatoid arthritis. Rev. parag. reumatol. [Internet]. 2015 Jul. 29 [cited 2025 Nov. 16];1(1):2-10. Available from: https://revista.spr.org.py/index.php/spr/article/view/7

Abstract

Objective: the aim of these recommendations is to be a reference for rheumatologists and other professionals involved in the treatment of rheumatoid arthritis, who are using or are about to use biologic therapy (Bt). Methods: for the search of bibliographic material a web search was performed using ebdatabases such as Pubmed and websites of various scientific societies of rheumatology and the data was classified according to quality of evidence. The document was approved by consensus between all the members of the Paraguayan Society of rheumatology (SPr). Results: recommendations were produced for use of biological therapy on patients with rheumatoid arthritis. these include: disease evolution, therapeutic objective, treatment plan, indication of Bt, risk management before the use of Bt, risk management during follow-up, attitude to adverse events, and attitude to special situations. Conclusions: the SPR recommendations for the use of biologic therapies are presented. these recommendations are not intended to serve as a therapeutic protocol but to improve the quality of care and help in making therapeutic decisions.
PDF (Spanish)
HTML (Spanish)

References

(1) Grigor C, Capell H, Sttirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid (the TOCIRA study): a single-blind radomised cintrolled trial. Lancey. 2004;364:263-9.

(2) Nell VP, Machold KP, Elberg G, Stamm TA, Uffmann M, Smolen JS. Benefit of a very early referral and very early therapy with diseasemodiflying anti-rheumtic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford).2004;43:906-914.

(3) Josef S Smolen, Robert Landewé, Ferdinand C Breedveld et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964–975.

(4) Wassenberg S, Rau R, Steinfeld P, et al. Very low-dose prednisolone in early rheumatoid arthritis retard radiographic progression over two years: multicenter, double blind placebo-controlled trial. Arthriitis Rheum 2005;52:3371-80.

(5) Jesús Tornero Molina , Raimon Sanmartí Sala , Vicente Rodríguez Valverde et al. Actualización del documento consenso de la Sociedad Española de reumatología sobre el uso de terapias biológicas en artritis reumatoide. Reumatol clin 2010; 6 (1): 23-36.

(6) Sociedad Española de Reumatología. Actualización de la guía practica para el manejo de la artritis reumatoide en España 2011. htpp://www.ser.es.

(7) Jasvinder A. Singh, Daniel E. Furst, Aseem Bharat et al. 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care & Research 2012; 64 (5): 625-639.

(8) Juan Gómez Reino, Estíbaliz Loza, José Luis Andreu et al. Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas. Reumatol Clin 2011; 7(5): 284-298.

(9) Smolen JS, Breedveld FC, Shiff MH, Kalden JR, Emery P, Eberl G, et al. A simplied disease activity index for rheumatoid arthritis for use in clinal practice. Rheumatology (oxford). 2003;42:244-57.

(10) Aletha D, Smolen J, The Simplified Disease activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a rewied of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005:23(Suppl 39):100-8.

(11) Medina Rodriguez F, Terapia biológica e infecciones. Reumatol Clin. 2006;2(6):302-12.

(12) Rodríguez Lozano C. Seguridad de las terapias biológicas: nuevos datos de BIOBADASER. Reumatol Clin. 2011;6(3):1–6.

(13) Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, on behalf of the BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122–7.

(14) Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients

treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005; 52:1766-72.

(15) Caroll MB, Forgione MA, Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a litrature review and potencial mechanisms of action. Clin Rheumatol 2010;29:1021-9.

(16) Ferri C, ferracioli G Ferrari D, Galeazi M, Lapadula G, Montecucco C, et al. Safety on anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infecction. J Rheumatol. 2008;35:1944-9.

(17) van Assen S, Agmon - Levin N, Elkayam O y col. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414-422.

Downloads

Download data is not yet available.